Population-adjusted indirect comparisons, developed in the 2010s, enable comparisons between two treatments in different studies by balancing patient characteristics in the case where individual patient-level data (IPD) are available for only one study. Health technology assessment (HTA) bodies increasingly rely on these methods to inform funding…

This research seeks to describe the continuing predicament of R&D funding in the U.S. and to provide support for a return to higher R&D spending as a proportion of GDP to maintain American leadership in innovation. Historically, government investment has funded most foundational scientific research leading to technological advances in…

Public funding for biomedical research is often justified as a means to encourage development of more (and better) treatments for disease. However, few studies have investigated the relationship between these expenditures and downstream pharmaceutical innovation. In particular, although recent analyses have shown a clear contribution of federally…

Observers say the research effort to develop drugs to combat acquired immune deficiency syndrome (AIDS) is increasingly well-funded but badly coordinated, with many universities not willing or not able to pull their weight. (MSE)

In recent years the scope and application of intellectual property rights has been expanded remarkably in the area of medical research and development. This has strengthened the role of the private sector in developing and producing new medicinal drugs. However, medical research is usually close to a pure public good and thus not efficiently…